Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04 ...

Azenta logo 5 medical stocks growing earnings by triple digits Azenta (NASDAQ:AZTA) reported fiscal first-quarter 2026 revenue of $149 million, up 1% on a reported basis but down 1% organically, as continued macro uncertainty and cautious capital spending weighed on parts of its portfolio. Management reaffirmed full-year guidance calling for 3% to 5% organic revenue growth and roughly 300 basis points of adjusted EBITDA margin expansion, while acknowledging that the turnaround “will not be a straight ...

Azenta (NasdaqGS:AZTA) Q1 2026 Earnings call February 04, 2026 08:30 AM ET Company ParticipantsAndrew Cooper - Director in Equity ResearchDavid Saxon - Managing DirectorJohn Marotta - President and CEOLawrence Lin - EVP and CFOMackenzie Strehle - Senior Equity Research Associate in Life Science Tools & DiagnosticsPaul Knight - Managing DirectorYvonne Perron - Vice President, FP&A and Head of Investor RelationsConference Call ParticipantsBrendan Smith - Director and Senior Analyst in Life Science Tools and D ...

Azenta (NasdaqGS:AZTA) Q1 2026 Earnings call February 04, 2026 08:30 AM ET Company ParticipantsAndrew Cooper - Director in Equity ResearchDavid Saxon - Managing DirectorJohn Marotta - President and CEOLawrence Lin - EVP and CFOMackenzie Strehle - Senior Equity Research Associate in Life Science Tools & DiagnosticsPaul Knight - Managing DirectorYvonne Perron - Vice President, FP&A and Head of Investor RelationsConference Call ParticipantsBrendan Smith - Director and Senior Analyst in Life Science Tools and D ...

Azenta (NasdaqGS:AZTA) Q1 2026 Earnings call February 04, 2026 08:30 AM ET Speaker6As a reminder, this conference is being recorded Wednesday, February 4, 2026. I will now turn the conference over to Yvonne Perron, Vice President, FP&A, and Investor Relations.Thank you, Operator, and good morning to everyone on the line today. We would like to welcome you to our earnings conference call for the first quarter of fiscal year 2026. Our first quarter earnings press release was issued before the open of the mark ...

© 2026 Azenta, Inc. • All rights reserved Safe Harbor Statement Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding future financial performance including our fiscal year 2026 guidance, business trends, market demand, operational initiatives, strategic priorities, and other expectations or forecasts. These statements are based ...

Exhibit 99.1 Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025 | | | | | | Quarter Ended | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | December | | September | | December | | | | | Dollars in millions, except per share data | 31, | | 30, | | 31, | | Change | | | | 2025 | | 2025 | | 2024 (1) | | Prior Qtr | Prior Yr. | | Revenue from Continuing Operations | $ | 149 | $ | 159 | $ | 147 | (7)% | 1% | | Organic growth | | | | | | | | (1)% | | Sample Management S ...

BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended | Dolla ...

Financial Data and Key Metrics Changes - The company ended the fiscal year with a strong cash balance of $546 million, providing financial flexibility for strategic investments and shareholder returns [3] - Fiscal 2025 was described as a turnaround year, with growth in core businesses and meaningful margin expansion despite a challenging macro environment [2] Business Line Data and Key Metrics Changes - Specific data on individual business lines was not provided in the meeting, but the overall performance indicated growth in core businesses [2] Market Data and Key Metrics Changes - No specific market data or key metrics changes were discussed during the meeting [2][3] Company Strategy and Development Direction - The company outlined a multi-year strategic roadmap during an Investor Day, which includes a $250 million share repurchase program [3] - A definitive agreement to divest B Medical was announced, with the transaction expected to close by March 31, 2026, indicating a focus on streamlining operations [3] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's leadership and operational momentum, positioning Azenta for durable growth and long-term profitable value creation for shareholders [3] Other Important Information - The meeting included the election of directors, a non-binding advisory vote on executive compensation, and the ratification of independent auditors for fiscal year 2026 [7][10] Q&A Session Summary - No specific questions or answers were recorded in the provided content, as the meeting primarily focused on formal business and strategic updates [2][3]

Financial Data and Key Metrics Changes - The company ended the fiscal year with a strong cash balance of $546 million, providing financial flexibility for strategic investments and shareholder returns [3] - Fiscal 2025 was described as a turnaround year, with growth in core businesses and meaningful margin expansion despite a challenging macro environment [2] Business Line Data and Key Metrics Changes - Specific data on individual business lines was not provided in the meeting, but the overall performance indicated growth in core businesses [2] Market Data and Key Metrics Changes - No specific market data or key metrics changes were discussed during the meeting [2][3] Company Strategy and Development Direction - The company outlined a multi-year strategic roadmap during an investor day, which includes a $250 million share repurchase program [3] - A definitive agreement to divest B Medical was announced, with the transaction expected to close by March 31, 2026, indicating a focus on streamlining operations [3] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's leadership and operational momentum, positioning Azenta for durable growth and long-term value creation for shareholders [3] - The management acknowledged the challenging macro environment but emphasized the successful execution of a disciplined strategy [2] Other Important Information - The meeting included the election of directors, a non-binding advisory vote on executive compensation, and the ratification of the appointment of PwC as independent auditors for fiscal year 2026 [7][10] Q&A Session Summary - No specific questions or answers were recorded during the meeting, as it primarily focused on formal business and proposals [10][19]